Integrated BioPharma, Inc. (INBP)
OTCMKTS: INBP · Delayed Price · USD
0.200
0.00 (0.00%)
Jul 25, 2024, 4:00 PM EDT - Market closed
Integrated BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Year Ending | TTM | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 50.57 | 50.67 | 56.25 | 63.56 | 52.77 | 49.98 | Upgrade
|
| Revenue Growth (YoY) | -0.75% | -9.91% | -11.51% | 20.45% | 5.59% | 14.34% | Upgrade
|
| Cost of Revenue | 46.98 | 46.61 | 49.69 | 54.08 | 46.04 | 43.76 | Upgrade
|
| Gross Profit | 3.59 | 4.06 | 6.55 | 9.48 | 6.73 | 6.22 | Upgrade
|
| Selling, General & Admin | 3.66 | 3.94 | 3.81 | 3.7 | 3.47 | 3.52 | Upgrade
|
| Operating Expenses | 3.66 | 3.94 | 3.81 | 3.7 | 3.47 | 3.52 | Upgrade
|
| Operating Income | -0.07 | 0.12 | 2.75 | 5.78 | 3.26 | 2.7 | Upgrade
|
| Interest Expense | -0.04 | -0.05 | -0.13 | -0.26 | -0.4 | -0.63 | Upgrade
|
| Interest & Investment Income | 0.05 | 0.04 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | - | 0.01 | 0.06 | 0.05 | 0.09 | Upgrade
|
| EBT Excluding Unusual Items | -0.06 | 0.11 | 2.63 | 5.59 | 2.91 | 2.16 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -0.01 | -0.06 | 0 | 0.18 | -0.12 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | 0 | 0.02 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 1.66 | - | - | Upgrade
|
| Pretax Income | -0.06 | 0.1 | 2.6 | 7.25 | 3.09 | 2.04 | Upgrade
|
| Income Tax Expense | 0.05 | 0.13 | -1.24 | -0.77 | -1.02 | 0.35 | Upgrade
|
| Net Income | -0.12 | -0.03 | 3.84 | 8.01 | 4.11 | 1.69 | Upgrade
|
| Net Income to Common | -0.12 | -0.03 | 3.84 | 8.01 | 4.11 | 1.69 | Upgrade
|
| Net Income Growth | - | - | -52.10% | 95.06% | 143.36% | 148.60% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 32 | 32 | 31 | 30 | Upgrade
|
| Shares Change (YoY) | -1.46% | -7.34% | 0.65% | 3.07% | 5.31% | -2.41% | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | 0.13 | 0.27 | 0.14 | 0.06 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.00 | 0.12 | 0.25 | 0.13 | 0.06 | Upgrade
|
| EPS Growth | - | - | -52.00% | 92.31% | 122.81% | 296.61% | Upgrade
|
| Free Cash Flow | -0.48 | 1.12 | 3.61 | 2.76 | 1.13 | -0.09 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | 0.04 | 0.11 | 0.09 | 0.04 | -0.00 | Upgrade
|
| Gross Margin | 7.09% | 8.01% | 11.65% | 14.92% | 12.75% | 12.45% | Upgrade
|
| Operating Margin | -0.14% | 0.24% | 4.88% | 9.10% | 6.18% | 5.41% | Upgrade
|
| Profit Margin | -0.23% | -0.07% | 6.82% | 12.61% | 7.78% | 3.38% | Upgrade
|
| Free Cash Flow Margin | -0.95% | 2.20% | 6.41% | 4.33% | 2.13% | -0.17% | Upgrade
|
| EBITDA | 0.24 | 0.47 | 3.08 | 6.12 | 3.57 | 3.03 | Upgrade
|
| EBITDA Margin | 0.48% | 0.93% | 5.48% | 9.63% | 6.77% | 6.05% | Upgrade
|
| D&A For EBITDA | 0.32 | 0.35 | 0.34 | 0.34 | 0.31 | 0.32 | Upgrade
|
| EBIT | -0.07 | 0.12 | 2.75 | 5.78 | 3.26 | 2.7 | Upgrade
|
| EBIT Margin | -0.14% | 0.24% | 4.88% | 9.10% | 6.18% | 5.41% | Upgrade
|
| Effective Tax Rate | - | 134.00% | - | - | - | 17.34% | Upgrade
|
Source: S&P Capital IQ. Standard template.